Government should invest in clinical trials

June 9, 2015 News BioVox

The government should invest each year a minimum of 10 to 15 million euros in publicly funded clinical trial according to the Belgian Health Care Knowledge Centre (KCE). Not all health care problems are addressed by the pharmaceutical industry. 

Pharmaceutical companies rarely compare a drug with another type of treatment. Think for example of the comparison between the effect of antidepressants and psychotherapy. Companies must demonstrate that their new product is safe and effective, but actually that is not always sufficient. One of the basic questions is also whether it works better than existing treatments. 

Therefore, the KCE believes that the government also needs to invest in clinical studies, as is already happening in several other countries. This is permissible, provided that the study subjects are carefully selected and that a solid professional infrastructure is available. Sufficient attention should be given to the publication and application of the results for decision-making concerning reimbursement in daily practice.  According to Dr. Frank Hulstaert, researcher at the KCE specializing in clinical trials, there should be more international cooperation. For instance, this would be very beneficial for studies on rare diseases.

(Source: De Standaard)

Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter